Рак лёгких

Roche gets a lung cancer win with its KRAS drug divarasib

Roche gets a lung cancer win with its KRAS drug divarasib STAT

New targeted therapy improved survival for patients with KRAS-mutated lung cancer

Patients with previously treated advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) lived significantly longer and saw improved disease control when treated with the next-generation KRAS-targeted therapy divarasib, according to researchers from The University of Texas MD Anderson Cancer Center.

'Magic Drug' Reduces Risk of Death by 44% in Lung Cancer Trial

'Magic Drug' Reduces Risk of Death by 44% in Lung Cancer Trial MedPage Today

Lung Cancer Blood Test May Help Predict Treatment Outcomes Before Surgery

Lung Cancer Blood Test May Help Predict Treatment Outcomes Before Surgery Inside Precision Medicine

Immunotherapy combo extends survival for patients with aggressive small cell lung cancer, based on trial results

In patients with extensive-stage small cell lung cancer (ES-SCLC), tarlatamab, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy extended median overall survival by more than eight months, more than tripled progression-free survival and reduced the risk of death by 58% compared to…

Metabolic vulnerability identified in small cell lung cancer

Researchers at the University of Cologne have demonstrated that, while various cellular states of small cell lung cancer are equally dependent on the amino acid cysteine, they react differently when deprived of it. While some cancer cells subsequently die via ferroptosis—a form of cell death in which harmful oxidized…

Pumitamig Combo Yields Activity in Metastatic Non–Small Cell Lung Cancer

Imfinzi plus Imdelltra could reshape first-line small cell lung cancer treatment after Phase III survival benefit

Imfinzi plus Imdelltra could reshape first-line small cell lung cancer treatment after Phase III survival benefit AllSci

Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study

Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study BioSpace

ESMO26: Key data breathing new life into the lung cancer field

ESMO26: Key data breathing new life into the lung cancer field Clinical Trials Arena

Roche’s divarasib cuts risk of death by 44% in lung cancer trial

Roche’s divarasib cuts risk of death by 44% in lung cancer trial MedWatch

New lung cancer drug adds nearly six months of survival stomach cancer treatment doubles it

New lung cancer drug adds nearly six months of survival stomach cancer treatment doubles it Ynetnews

Immunotherapy combo extends survival for patients with aggressive small cell lung cancer, based on trial results presented by Dana-Farber at ESMO Congress 2026 | Newswise

Immunotherapy combo extends survival for patients with aggressive small cell lung cancer, based on trial results presented by Dana-Farber at ESMO Congress 2026 | Newswise Newswise

Tennessee Oncology Researchers Help Lead Global Trial of Next-Generation Lung Cancer Therapy

Tennessee Oncology Researchers Help Lead Global Trial of Next-Generation Lung Cancer Therapy BioSpace

Immunotherapy Combo Extends Survival for Patients With Aggressive Small Cell Lung Cancer

Immunotherapy Combo Extends Survival for Patients With Aggressive Small Cell Lung Cancer Cancer Health